Apollomics (APLM) Short Interest Ratio & Short Volume

Short interest is the volume of Apollomics shares that have been sold short but have not yet been covered or closed out. As of June 15th, investors have sold 7,700 shares of APLM short. 0.94% of Apollomics' shares are currently sold short. Learn More on Apollomics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.94% of Apollomics' floating shares are currently sold short.

Apollomics saw a decline in short interest during the month of June. As of June 15th, there was short interest totaling 7,700 shares, a decline of 30.0% from the previous total of 11,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Apollomics currently has issued a total of 1,100,000 shares. Some of Apollomics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Apollomics currently has a public float of 815,100 shares.

0.94% of Apollomics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Apollomics: Tempest Therapeutics, Inc. (11.75%), Dare Bioscience, Inc. (0.53%), Cara Therapeutics, Inc. (1.74%), Passage Bio, Inc. (3.38%), Cadrenal Therapeutics, Inc. (1.47%), Tenax Therapeutics, Inc. (8.58%), Cyclo Therapeutics, Inc. (3.55%), BioAtla, Inc. (7.97%), FibroGen, Inc (5.10%), CalciMedica Inc. (1.73%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($69.26 billion), Invesco QQQ ($25.22 billion), iShares Russell 2000 ETF ($20.33 billion), iShares 20+ Year Treasury Bond ETF ($9.99 billion), MicroStrategy Incorporated ($9.12 billion), Canadian Natural Resources Limited ($6.73 billion), SPDR S&P Biotech ETF ($6.52 billion), Invesco S&P 500 Equal Weight ETF ($5.60 billion), Financial Select Sector SPDR Fund ($4.64 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.59 billion). View all of the most shorted stocks.

Short selling APLM is an investing strategy that aims to generate trading profit from Apollomics as its price is falling. APLM shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Apollomics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of APLM, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including APLM, twice per month. The most recent reporting period available is June, 15 2025.